ICON and LEO Pharma join forces on clinical trial mission
Pharma Times
MARCH 10, 2023
Collaboration will concentrate on launching and running studies within medical dermatology
Digital clinical trials: Trends to watch in 2023
Pharmaceutical Technology
APRIL 13, 2023
Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.
Clinical Trials 
130
130 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
June 26, 2024: Using ChatGPT to Facilitate Informed Medical Consent, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
JUNE 26, 2024
Mirza is chief resident in the Department of Dermatology at the Warren Alpert Medical School of Brown University. The post June 26, 2024: Using ChatGPT to Facilitate Informed Medical Consent, in This Week’s PCT Grand Rounds appeared first on Rethinking Clinical Trials. Join the online meeting.
Dermatology 144
144 
Digital tools driving innovative clinical trials
pharmaphorum
JULY 8, 2022
The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. Source: Izmailova et al, 2017.
Clinical Trials 100
100 
Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development
FDA Law Blog
NOVEMBER 10, 2024
Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2
Production 69
69 
PI Focus: Building Relationships Through Clinical Trials in the United Kingdom
Velocity Clinical Research
JULY 18, 2023
Born and trained in Egypt, he moved to the UK several years ago after working as a general practitioner there and deciding he loved the country and the clinical trial opportunities it offered. To join a clinical trial at Velocity, visit velocityclinicaltrials.com.
Treatment options for Crohn’s disease expand after Rinvoq approval
Pharmaceutical Technology
MAY 19, 2023
Clinical response was observed after just two weeks in some cases. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology. A maintenance study showed the same effects at 52 weeks. In patients with severe symptoms, a dosage of 30mg can be considered.
FDA Approval 264
264 
STAT+: Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices
STAT News
DECEMBER 2, 2022
And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.
Health Canada to review Arcutis’ roflumilast cream NDS for plaque psoriasis
Pharmaceutical Technology
JULY 12, 2022
A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials. Health Canada has provided a target action date of 30 April next year.
Dermatology 162
162 
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.
Use of medical imaging in clinical trials expanding
Outsourcing Pharma
FEBRUARY 2, 2021
While the technology has been found mostly in dermatological applications, its use in studies is expanding, according to Illingworth Research Group.
Standardized Rater Training to Meet the Demands of Dermatology Growth and Complexities
WCG Clinical
OCTOBER 9, 2023
The dermatology market is embarking on tremendous growth and sponsors need to be ready. Over the last 12 months, dermatology-focused studies have increased by roughly 20%, with top focus areas including psoriasis, atopic dermatitis, and alopecia. This rapid growth brings new challenges. Efficiency and speed are critical.
Dermatology 59
59 
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
UNION Therapeutics-Innovent’s collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular’s CAPLYTA Phase III study
Delveinsight
SEPTEMBER 28, 2021
Innovent, UNION Therapeutics Set to Advance Dermatology Market in China. Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast , a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China.
Ensuring successful digital outreach and retention in atopic dermatitis trials
pharmaphorum
JULY 5, 2022
Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than 500 dermatology clinical trials currently underway, it is often heard that there is a ‘’competition for participants’’. Patient recruitment for moderate or severe atopic dermatitis.
Trials 118
118 
4 Benefits Of Clinical Trial Participation
Olympian Clinical Research
FEBRUARY 26, 2021
Clinical trials are research studies designed to evaluate or test a medical, surgical, or behavioral intervention. Most recently, clinical trials have gained recognition through the development and testing of Covid-19 vaccines. Today we’re taking some time to highlight a few of the biggest ones!
Animated and Live Action Content Delivers Precise Training for Dermatology Studies
WCG Clinical
MARCH 30, 2023
Uniform Live Action Training Using InvestigatorSpace Speeds Up Study Start Times In one case, a global pharmaceutical company used WCG’s training solutions to support two dermatology studies they were running. Study teams engaged with the training content throughout the trial and asked questions through the InvestigatorSpace platform.
Dermatology 52
52 
Orismilast Closer to Phase III as a Promising Oral Treatment for Atopic Dermatitis
XTalks
SEPTEMBER 30, 2024
Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, the study highlighted significant improvements in key disease markers, positioning orismilast as a potential breakthrough in atopic dermatitis management.
Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials
VirTrial
JULY 7, 2024
In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.
Optimizing Endpoint Assessments for Dermatology Studies
WCG Clinical
SEPTEMBER 20, 2023
Welcome to the recorded session of ‘Optimizing Endpoint Assessments for Dermatology Studies.’ In this insightful webinar, we take a deep dive into dermatology trials and discuss how standardizing rater qualification and training can solve common challenges and protect the quality and integrity of endpoint data.
Dermatology 40
40 
Lebrikizumab Could Soon Be a New Treatment for Atopic Dermatitis
XTalks
APRIL 17, 2023
In clinical trials, patients experienced significantly clearer skin and less interference with sleep due to itch when taking lebrikizumab compared to placebo. The ADvocate1 and ADvocate2 Phase III studies were published in the New England Journal of Medicine and the British Journal of Dermatology , respectively.
Dermatology 97
97 
Grand Rounds June 28, 2024: Using ChatGPT to Facilitate Truly Informed Medical Consent (Fatima N. Mirza, MD, MPH)
Rethinking Clinical Trials
SEPTEMBER 24, 2024
Mirza, MD, MPH Chief Resident Department of Dermatology Warren Alpert Medical School of Brown University Slides Keywords Artificial Intelligence; ChatGPT; Informed Consent Key Points Artificial Intelligence (AI), when implemented thoughtfully in clinical settings, can lead to meaningful results for patients.
Clinical Trials 100
100 
Zoryve Produces Promising Results in Dermatologic Conditions Across Recent Trials
Pharmaceutical Commerce
JANUARY 16, 2024
Zoryve (roflumilast) shows efficacy in seborrheic dermatitis and atopic dermatitis in clinical trials.
Dermatology 52
52 
Povorcitinib Phase III Results Stir Mixed Signals for Incyte and Investors
XTalks
MARCH 18, 2025
Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market.
Trials 59
59 
The siRNA STP705 by Sirnaomics Has Promise for Treating in situ Squamous Cell Carcinoma (isSCC)
XTalks
JUNE 20, 2022
The results of their Phase IIa STP705 clinical study were published in the Journal of Drugs in Dermatology , a peer-reviewed medical journal of dermatology that was established in 2002. Clinical Trial Outcomes of isSCC Treatment with STP705. STP705 — A Promising siRNA Candidate Against isSCC.
RNA 96
96 
Verrica’s Dr. Lawrence Eichenfield Speaks About FDA Approval of New Drug for Common Skin Infection – Xtalks Life Science Podcast Ep. 121
XTalks
AUGUST 2, 2023
Eichenfield was also the principal investigator on clinical trials evaluating YCANTH. Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions.
Life Science 52
52 
Pivotal results from Trinity clinical trial for the chronic condition atopic dermatitis
Scienmag
MAY 21, 2021
The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at […].
Topical steroid withdrawal diagnostic criteria defined by researchers
Medical Xpress
MARCH 14, 2025
Scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) identified treatments that could be studied in clinical trials for the condition based on their potential to lower levels of the chemical compoundcalled nicotinamide adenine dinucleotide (NAD+), a form of vitamin B3.
Research 52
52 
Sofdra for Sweat Relief: A New Breakthrough in Primary Axilliary Hyperhidrosis Treatment
XTalks
JUNE 26, 2024
Hyperhidrosis is the third most prevalent dermatological condition in the US, affecting roughly 15.3 While Sofdra stands out as the first new chemical entity approved for primary axillary hyperhidrosis, the market for hyperhidrosis treatments includes other medications and clinical trials.
Clinical Trials 103
103 
Breaking News: German CRO Opens Office In North Carolina
ECRG Media's Clinical Research Podcast
SEPTEMBER 11, 2018
A german CRO that specializes in Dermatology clinical trials has decided to open an office in North Carolina. Not in the Biotech and clinical research hub of the Raleigh/Durham Triangle but in the coast near Wilmington. Have you heard about ProInnovera before or have an interest in Dermatology?
Dermatology 52
52 
Breaking News: German CRO Opens Office In North Carolina
ECRG Media's Clinical Research Podcast
SEPTEMBER 11, 2018
A german CRO that specializes in Dermatology clinical trials has decided to open an office in North Carolina. Not in the Biotech and clinical research hub of the Raleigh/Durham Triangle but in the coast near Wilmington. Have you heard about ProInnovera before or have an interest in Dermatology?
Dermatology 52
52 
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
The Pharma Data
OCTOBER 29, 2020
30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. 10x ULN were observed in patients in Olumiant clinical trials.
Dermatology 52
52 
Nemolizumab Delivers Significant Itch-Relief in Phase III Clinical Trials
XTalks
AUGUST 2, 2024
These trials reveal nemolizumab’s potential to significantly improve key aspects of atopic dermatitis, including skin lesions, itch and sleep disturbance, in both adolescent and adult patients with moderate-to-severe cases.
Clinical Studies Support DermaSensor’s Skin Cancer Detection Device
XTalks
MARCH 24, 2023
The company recently presented a pooled analysis from clinical studies of their DermaSensor skin cancer detection device at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The results presented were from two of DermaSensor’s four clinical studies that were submitted to the US Food and Drug Administration (FDA).
Dermatology 97
97 
Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults
XTalks
MAY 31, 2022
XTALKS WEBINAR: All Means All: The Road to Inclusivity in Clinical Trials. Register for this free webinar to learn what the FDA’s new draft guidance means for diverse and inclusive trials. Clinical Trials of Vtama. At Dermavant, we are committed to advancing novel, patient-focused innovation in immuno-dermatology.
FDA Approval 98
98 
Rebuilding Clinical Trials in the Image of Patient Need: Key Takeaways from Reuters Pharma Clinical 2021
Pharma Marketing Network
APRIL 30, 2021
Clinical trials may be one of the very last bastions of a non-customer-focused approach within the pharmaceutical industry. Across the board, from rheumatology to neurology, outcomes that matter most to patients, have traditionally not been captured in clinical trials. How do we increase the diversity of clinical trials?
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
A Closer Look At Hidradenitis Suppurativa: Disease, Causes, & Treatment
Olympian Clinical Research
AUGUST 5, 2020
Although severe cases of HS can appear unsightly, with intense bruising or discoloration, pus, and boils; the condition is merely a type of dermatological condition the same as acne, psoriasis, and countless other skin conditions. . HS is not caused by lack of hygiene.
Let's personalize your content